DAY BY DAY Maintains EssilorLuxottica Société anonyme

DAY BY DAY kept a Buy on EssilorLuxottica (OTCPK:ESLOY) on Dec. 9, 2025, with an average one-year analyst price target of $193.21 (range $146.42–$224.03), implying ~72.48% upside from the closing price of $112.02; consensus forecasts project annual revenue of $27,882MM (+2.35%) and non-GAAP EPS of 7.85. Institutional interest has risen recently: 23 funds now hold the ADR, total institutional shares climbed 164.91% to 185k and average portfolio weight increased to 0.16% (+39.24%), with notable position increases such as BlackRock GA Dynamic Equity Fund (reported 103k shares). The combination of sizable implied upside from analysts and visible institutional accumulation signals renewed positive sentiment toward EssilorLuxottica, though the wide price-target range reflects some analyst dispersion on valuation.

Analysis

DAY BY DAY maintained a Buy on EssilorLuxottica Société anonyme - Depositary Receipt (OTCPK:ESLOY) on December 9, 2025, citing an average one‑year analyst price target of $193.21 (range $146.42–$224.03), which implies a 72.48% upside from the closing price of $112.02. The wide target range highlights analyst dispersion on valuation even as the consensus target sits materially above the current market price.

Consensus fundamental projections show modest top‑line expansion with projected annual revenue of $27,882MM, up 2.35%, and a projected annual non‑GAAP EPS of 7.85; these figures suggest upside in valuation must be driven by earnings/margin improvement rather than aggressive revenue growth. Institutional activity has strengthened: 23 funds report positions (up 1 owner or 4.55%), average portfolio weight rose to 0.16% (+39.24%), and total institutional shares increased 164.91% to 185k, led by BlackRock GA Dynamic Equity Fund reporting 103k shares in the latest filing.

Market signals are moderately positive (sentiment_score 0.55, market_impact_score 0.35), so the narrative is bullish but contingent. The combination of significant implied upside and visible institutional accumulation supports a constructive case, yet the analyst target dispersion and only 2.35% revenue growth warrant monitoring of forthcoming earnings, margin trends and continued fund inflows as confirmation before materially increasing exposure.

Key Decisions for Investors

• Consider initiating or incrementally adding a position on price weakness given the 72.48% analyst‑implied upside, while sizing positions modestly until earnings and margin improvement confirm the valuation case
• Watch institutional filings and monthly ownership updates (total institutional shares rose 164.91% to 185k and BlackRock increased to 103k) as a validation signal before increasing exposure further
• Use the analyst range ($146.42–$224.03) to set tiered profit‑taking levels and maintain risk controls if revenue/EPS execution diverges from the projected revenue of 27,882MM and non‑GAAP EPS of 7.85